天眼查商业履历信息显示，雅本化学股份有限公司，成立于2006年，位于苏州市，是一家以从事化学原 料和化学制品制造业为主的企业。企业注册资本96330.9471万人民币，实缴资本96330.9471万人民币。 公司法定代表人为蔡彤。 通过天眼查大数据分析，雅本化学股份有限公司共对外投资了10家企业，参与招投标项目19次，知识产 权方面有商标信息37条，专利信息73条，此外企业还拥有行政许可16个。 金融界消息 截至2025年8月1日收盘，雅本化学（300261）报收于8.65元，下跌1.82%，换手率10.91%， 成交量102.27万手，成交金额8.99亿元。 资金流向方面，今日主力资金净流出2649.03万元，占比成交额2.95%。其中，超大单净流出1827.39万 元、占成交额2.03%，大单净流出821.63万元、占成交额0.91%，中单净流出流出2165.26万元、占成交 额2.41%，小单净流入4814.29万元、占成交额5.35%。 雅本化学最新一期业绩显示，截至2025一季报，公司营业总收入3.16亿元、同比增长43.52%，归属净利 润1275.65万元，同比增长72.01%，扣非净利润142 ...

Group 1 - China Foreign Transport plans to increase its stake in Antong Holdings by 300 million to 600 million yuan, with a maximum purchase price of 3.2 yuan per share [2] - Chipone Technology expects its revenue for the second quarter of 2025 to be approximately 584 million yuan, representing a quarter-on-quarter growth of 49.9% [1] - Nova Star Cloud intends to repurchase shares worth 75 million to 150 million yuan for employee stock ownership plans [5] Group 2 - Cangge Mining reported a 38.8% year-on-year increase in net profit for the first half of 2025, with a proposed cash dividend of 10 yuan per 10 shares [7] - Jiangfeng Electronics' subsidiary plans to purchase 97 machine tools for a total estimated value of 233 million yuan to expand production capacity [9] - Aorikin plans to invest approximately 442 million yuan in a new can production line in Thailand and 647 million yuan in Kazakhstan [10]

Core Viewpoint - Yabao Chemical announced the termination of its acquisition of Gansu Haotian Technology Co., Ltd. after five months of negotiations, marking the third failed IPO attempt for Haotian Technology in two years [2][4]. Group 1: Acquisition Termination - On July 30, Yabao Chemical stated its intention to terminate the acquisition of Haotian Technology's existing shares and/or subscription of new registered capital [3]. - The decision was made after Yabao Chemical and Haotian Technology failed to reach an agreement on core terms that aligned with Yabao's business development needs [4]. - Yabao Chemical's strategy focuses on large clients, while Haotian Technology's business model is oriented towards multiple clients, leading to a misalignment in strategic goals [4]. Group 2: Haotian Technology's Background - Haotian Technology, established in 2009 with a registered capital of 45 million yuan, specializes in the R&D, production, and sales of specialty APIs and intermediates [3]. - The company has faced challenges, including a failed IPO attempt in 2023, where it aimed to raise 823 million yuan for various projects but later withdrew its application [5]. Group 3: Future Directions for Yabao Chemical - Despite the termination of the acquisition, Yabao Chemical plans to strengthen its business in pharmaceutical intermediates and has signed a strategic supply agreement with Jiangsu Hengrui Medicine Co., Ltd. [6]. - The agreement aims to foster a partnership for technological innovation and quality upgrades in specific pharmaceutical intermediates and APIs [6]. - Yabao Chemical remains open to exploring other suitable acquisition targets in the future [6]. Group 4: Financial Status and Risks - Yabao Chemical has reported consecutive losses over the past two years but assesses that the risk of being classified as "ST" (special treatment) is low, as the current regulations require three consecutive years of losses along with an adverse audit conclusion [7].

雅本化学：与恒瑞医药签署供应战略协议 8月1日晚，雅本化学（300261）发布公告称，公司与江苏恒瑞医药股份有限公司签署《供应战略协 议》，建立面向未来的战略合作伙伴关系。双方将共同推动特定医药中间体及原料药（API）产品的技 术创新与质量升级，强化医药产业链关键环节的协同竞争力。协议有效期为10年，自2025年8月1日起生 效。 资料显示，雅本化学成立于2006年1月，主营业务是创新农药中间体、医药中间体的研发、生产和销 售。 所属行业：基础化工–农化制品–农药 巍华新材：拟收购禾裕泰控股权 8月1日晚，巍华新材（603310）发布公告称，公司与浙江欣禾生物股份有限公司签署股权收购意向协 议，拟以现金方式收购江苏禾裕泰化学有限公司的控股权。此次收购旨在延伸公司产品链，发挥协同效 应，提升公司在行业内的综合竞争力。目前，收购事项尚处于筹划阶段。 资料显示，巍华新材成立于2013年10月，主营业务是研发、生产氯甲苯类和三氟甲基苯类系列产品。 所属行业：基础化工–化学制品–氟化工 富吉瑞：获得200.74万元政府补助 8月1日晚，富吉瑞（688272）发布公告称，公司近日收到政府补助200.74万元。该补助为与收 ...

格隆汇8月1日丨雅本化学(300261.SZ)公布，公司与恒瑞医药签署《供应战略协议》。双方就建立面向 未来的战略合作伙伴关系达成框架性协议，以共同推动协议产品的技术创新与质量升级，强化医药产业 链关键环节的协同竞争力，实现双方在医药先进制造领域的价值共赢。双方同意通过本协议建立以协议 产品全生命周期协同管理为核心的战略合作伙伴关系，共同构建涵盖工艺研发、商业化生产及持续性改 进的端到端协作机制。 本协议的履行将不仅带来即期业务贡献，更通过优化客户结构、提升抗风险能力、验证综合实力、深化 业务布局及强化品牌效应，为创新医药CDMO业务构筑坚实的中长期增长基础，驱动"2+X"战略特别是 创新医药核心支柱的加速发展。 ...

Core Viewpoint - The company Yabao Chemical has signed a strategic supply agreement with Heng Rui Pharmaceutical to establish a long-term partnership aimed at promoting technological innovation and quality upgrades in specific pharmaceutical intermediates and active pharmaceutical ingredients (API) [1] Group 1 - The agreement is a framework for a strategic cooperation relationship between the two companies [1] - The partnership aims to enhance the collaborative competitiveness in key segments of the pharmaceutical industry chain [1] - The agreement will remain effective until July 31, 2035, indicating a long-term commitment [1]

雅本化学（300261）(300261.SZ)公告，公司与恒瑞医药（600276）签署《供应战略协议》。双方就建 立面向未来的战略合作伙伴关系达成框架性协议，以共同推动特定医药中间体及原料药(API)产品的技 术创新与质量升级，强化医药产业链关键环节的协同竞争力，实现双方在医药先进制造领域的价值共 赢。该协议将长期生效，有效期直至2035年7月31日。 ...

Group 1 - The core viewpoint of the article is the strategic partnership established between Yabao Chemical and Hengrui Medicine through a supply strategic agreement aimed at collaborative management of the product lifecycle [1] - The agreement focuses on creating an end-to-end collaboration mechanism that includes process research and development, commercial production, and continuous improvement [1] - Yabao Chemical is confirmed as the strategic partner of Hengrui Medicine in the field of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) [1]

证券代码：300261 证券简称：雅本化学 公告编号：2025-058 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： 1、2025 年 8 月 1 日，雅本化学股份有限公司（以下简称"公司"或"雅 本化学"）与江苏恒瑞医药股份有限公司（以下简称"恒瑞医药"）签署《供 应战略协议》（以下简称"本协议"）。双方就建立面向未来的战略合作伙伴 关系达成框架性协议，以共同推动特定医药中间体及原料药（API）产品（以下 简称"协议产品"）的技术创新与质量升级，强化医药产业链关键环节的协同 竞争力，实现双方在医药先进制造领域的价值共赢。本协议为后续双方推进具 体项目合作奠定了基础，不涉及具体交易金额，最终能否实施尚存在不确定性， 敬请广大投资者注意投资风险。 2、本协议的签署预计对公司本年度经营业绩不会产生重大影响，对公司未 来年度经营业绩的影响需根据后续具体合作情况而定，并以审计机构年度审计 确认后的结果为准。敬请广大投资者注意风险。 3、本协议的签署不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组，无需提交公司董事会和股东会审议 ...

雅本化学公告，2025年8月1日，公司与恒瑞医药签署《供应战略协议》。双方就建立面向未来的战略合 作伙伴关系达成框架性协议，以共同推动特定医药中间体及原料药产品（API）的技术创新与质量升 级，强化医药产业链关键环节的协同竞争力，实现双方在医药先进制造领域的价值共赢。本协议为后续 双方推进具体项目合作奠定了基础，不涉及具体交易金额，最终能否实施尚存在不确定性。 ...